Financial News
Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A
May 03, 2023 at 14:20 PM EDT
Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) chief medical officer Dr Mark Bleakley speaks with Proactive soon after announcing final results for a Phase 1 clinical trial to assess pharmacokinetics and the safety of the company’s anti-inflammatory drug candidate IHL-675A. IHL-675A is a combination cannabinoid drug comprising cannabidiol (CBD) and hydroxychloroquine (HCQ) in a fixed dose combination.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
More News
View More
Hey SoundHound—Why Is Your Stock Suddenly on Fire? ↗
Today 14:27 EST
Is 2026 The Year to Load Up on Crypto Miners? ↗
Today 13:43 EST
Why SanDisk Just Had One of the Biggest Days in Its History ↗
Today 12:37 EST
Starbucks’ Turnaround Makes a Strong Case for Long-Term Hold ↗
Today 11:38 EST
Recent Quotes
View More
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
